Trials / Completed
CompletedNCT03777332
Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy
A 24-Month Phase Ib Multi-Center, Open Label, Single Arm Study to Evaluate the Safety of Intravitreal APL-2 Therapy in Patients Diagnosed With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Apellis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
Safety Assessment of APL-2 in Patients with Geographic Atrophy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PEGCETACOPLAN (APL-2) | Complement (C3) Inhibitor |
Timeline
- Start date
- 2018-11-05
- Primary completion
- 2021-04-01
- Completion
- 2021-04-01
- First posted
- 2018-12-17
- Last updated
- 2021-11-10
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03777332. Inclusion in this directory is not an endorsement.